A Phase 3 interventional study of TLK286 in Combination with Carboplatin and Doxorubicin HCl Liposome Injection in Ovarian Neoplasms, sponsored by Telik. Completed at 222 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-31.
Sponsored by Telik · Phase 3, Interventional, and Treatment
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.
2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.
This study's enrollment of 244 is above the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Telik is the lead sponsor of 20 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: TLK286 in Combination with Carboplatin
Drug: Doxorubicin HCl Liposome Injection
Experimental Arm
Active Comparator
Study Objectives
To demonstrate superiority in the objective response rate (ORR) of TLK286 in combination with carboplatin as compared to active control therapy with liposomal doxorubicin
Time frame: Every 8 Weeks
Showing the first 100 of 222 sites.
This study is completed, as verified in Jun 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Telik